|
"These results lead us to conclude that 9-NC (rubitecan) has significant activity in Ph-negative CML, CMML and possibly MDS."
Speaking at the symposium on novel agents and concepts in the management of hematologic malignancies, Dr. Jorge Cortes, associate internist and associate professor of medicine at the M.D. Anderson Cancer Center in Houston, presented preliminary results from an ongoing study on the efficacy of rubitecan in chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS). Of the 54 patients treated, 43 percent experienced either a complete response (6), partial response (10) or hematologic improvement (7).
"These results lead us to conclude that 9-NC (rubitecan) has significant activity in Ph-negative CML, CMML and possibly MDS," said Dr. Cortes.
"With 43 percent of these patients responding positively, we are extremely pleased to see the activity of rubitecan in CML, CMML and MDS, a deadly group of diseases which are notoriously difficult to treat," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "The data generated thus far validate our continuing belief that rubitecan may be effective in a wide variety of solid tumors and hematologic malignancies."
Rubitecan is a second-generation oral topoisomerase-I inhibitor that is in the latter stages of Phase III clinical trials for pancreatic cancer at over 200 medical centers nationwide.
Based in San Ramon, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer.
Source: SuperGen Inc.
CMLSupport Home Page This site was last updated on Sept. 16, 2000 Copyright © 2000 Jennifer M. Gangloff. These contents may not be reproduced in whole or in part without the express written permission of the author, or she will beat you up and stuff. |